Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: New processes and equipment to isolate and purify nucleic acids on surfaces are provided. The invention focuses on processes which use surfaces, for example, porous membranes, on which the nucleic acids are immobilized in a simple manner from the sample containing the nucleic acids and can be released again by way of simple procedural steps, whereby the simple performance of the process according to the invention makes it possible to perform the processes specifically in a fully automatic manner. An additional aspect of the present invention focuses on binding the nucleic acids to an immobile phase, especially to a membrane, in such a way and manner, that they can be released without difficulty during an additional reaction stage from this phase and, if desired, can be used in other applications, such as restriction digestion, RT, PCR or RT-PCR, or in any of the suitable analyses or enzyme reactions mentioned in the disclosure.

Abstract: New processes and equipment to isolate and purify nucleic acids on surfaces are provided. The invention focuses on processes which use surfaces, for example, porous membranes, on which the nucleic acids are immobilized in a simple manner from the sample containing the nucleic acids and can be released again by way of simple procedural steps, whereby the simple performance of the process according to the invention makes it possible to perform the processes specifically in a fully automatic manner. An additional aspect of the present invention focuses on binding the nucleic acids to an immobile phase, especially to a membrane, in such a way and manner, that they can be released without difficulty during an additional reaction stage from this phase and, if desired, can be used in other applications, such as restriction digestion, RT, PCR or RT-PCR, or in any of the suitable analyses or enzyme reactions mentioned in the disclosure.

Abstract: A process for the depletion or removal of endotoxins from preparations containing active ingredients designated for therapeutical use which are obtained from natural sources by genetic engineering and/or biotechnology by treatment with chromatographic material wherein said natural sources are lysed, the fractions obtained are optionally centrifuged, filtrated or treated with affinity chromatographic methods; said fractions are preincubated with an aqueous salt solution and detergents, treated with anion exchange material and then washed with another salt solution, and the active ingredients are eluted from the anion exchanger, followed by further purification in a per se known manner.

Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: A process for the depletion or removal of endotoxins from preparations containing active ingredients designated for therapeutical use which are obtained from natural sources by genetic engineering and/or biotechnology by treatment with chromatographic material wherein said natural source are lysed, the fractions obtained are optionally centrifuged, filtrated or treated with affinity chromatographic methods; said fractions are preincubated with an aqueous salt solution and detergents, treated with anion exchange material and then washed with another salt solution, and the active ingredients are eluted from the anion exchanger, followed by further purification in a per se known manner.

Abstract: A process for the depletion or removal of endotoxins from preparations containing active ingredients designated for therapeutical use which are obtained from natural sources by genetic engineering and/or biotechnology by treatment with chromatographic material wherein said natural sources are lysed, the fractions obtained are optionally centrifuged, filtrated or treated with affinity chromatographic methods; said fractions are preincubated with an aqueous salt solution and detergents, treated with anion exchange material and then washed with another salt solution, and the active ingredients are eluted from the anion exchanger, followed by further purification in a per se known manner.

Abstract: New processes and equipment to isolate and purify nucleic acids on surfaces are provided. The invention focuses on processes which use surfaces, for example, porous membranes, on which the nucleic acids are immobilized in a simple manner from the sample containing the nucleic acids and can be released again by way of simple procedural steps, whereby the simple performance of the process according to the invention makes it possible to perform the processes specifically in a fully automatic manner. An additional aspect of the present invention focuses on binding the nucleic acids to an immobile phase, especially to a membrane, in such a way and manner, that they can be released without difficulty during an additional reaction stage from this phase and, if desired, can be used in other applications, such as restriction digestion, RT, PCR or RT-PCR, or in any of the suitable analyses or enzyme reactions mentioned in the disclosure.

Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is hot down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.

Abstract: The present invention shows that DNA vaccine vectors can be improved by removal of CpG-N motifs and optional addition of CpG-S motifs. In addition, for high and long-lasting levels of expression, the optimized vector should include a promoter/enhancer that is not down-regulated by the cytokines induced by the immunostimulatory CpG motifs. Vectors and methods of use for immunostimulation are provided herein. The invention also provides improved gene therapy vectors by determining the CpG-N and CpG-S motifs present in the construct, removing stimulatory CpG (CpG-S) motifs and/or inserting neutralizing CpG (CpG-N) motifs, thereby producing a nucleic acid construct providing enhanced expression of the therapeutic polypeptide. Methods of use for such vectors are also included herein.

Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: New processes and equipment to isolate and purify nucleic acids on surfaces are provided. The invention focuses on processes which use surfaces, for example, porous membranes, on which the nucleic acids are immobilized in a simple manner from the sample containing the nucleic acids and can be released again by way of simple procedural steps, whereby the simple performance of the process according to the invention makes it possible to perform the processes specifically in a fully automatic manner. An additional aspect of the present invention focuses on binding the nucleic acids to an immobile phase, especially to a membrane, in such a way and manner, that they can be released without difficulty during an additional reaction stage from this phase and, if desired, can be used in other applications, such as restriction digestion, RT, PCR or RT-PCR, or in any of the suitable analyses or enzyme reactions mentioned in the disclosure.

Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: A process for the depletion or removal of endotoxins from preparations containing active ingredients designated for therapeutical use which are obtained from natural sources by genetic engineering and/or biotechnology by treatment with chromatographic material wherein

Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: The general field of the invention is a method for nucleic acid vaccination for animals to protect them from parvoviral infection. This invention is more particularly related to the preparation and use of parvoviral DNA and its administration to dogs, cats and mink so as to induce an immune response that can protect these animals from disease caused by virulante parvovirus. Nucleic acid immunogens are designed to include the antigenic portions of the parvoviral genome which are incorporated into bacterial plasmids. These plasmids produce the desired parvoviral gene product when introduced into host cells by transfection. Host cells transfected with the parvoviral immunogen expressing plasmids produce a stream ot antigenic proteins to which the host immune system will mount a protective immune response.

Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.

Abstract: A method for the purification and separation of nucleic acid mixtures by chromatography including adsorbing the nucleic acids to be separated and purified from a solution with a high concentration of salts (ionic strength) and/or a high concentration of alcohol on a substrate and subsequent desorbing from the substrate by means of a solution with lower concentration of salts (ionic strength).

Abstract: A process for the isolation and purification of nucleic acids and/or oligonucleotides for use in gene therapy wherein said nucleic acids and/or oligonucleotides are isolated or purified from an essentially biological source, characterized in that